Cinven to sell Amdipharm Mercury for $3.5 billion

Concordia Healthcare Corp. said Tuesday it has agreed to buy Amdipharm Mercury Ltd. for about $3.5 billion. The seller is Cinven. The $3.5 billion will consist of $1.2 billion cash, $700 million stock, the assumption of $1.4 billion in debt and a maximum performance-based cash earn-out of $220 million payable in fourth quarter 2016. Goldman, Sachs & Co., Credit Suisse, RBC Capital Markets and Jefferies are providing financing. London-based Amdipharm Mercury is pharmaceutical company.

DealsNorth AmericaUSBriefs